Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Accelerator Invests in Six New Startups

NEW YORK – Illumina said on Wednesday that its Illumina Accelerator program has invested in six new startups from around the world.

The firms include Acrobat Genomics, a Stanford University spinout that uses high-throughput CRISPR gene editing to fill its pipeline of novel therapeutics; Nusantics, a genomics company from Indonesia that is developing microbiome-related diagnostic tools tailored for the Indonesian and other Asian populations; and Pandora Biosciences, a South African neuroscience company building genetically diverse and physiologically relevant organoid-based disease models for drug development for complex neurological diseases.

In addition to seed funding, the firms gain access to Illumina sequencing systems and reagents, business guidance, genomics expertise, and fully operational lab space adjacent to Illumina's campuses in Cambridge, UK, or the San Francisco Bay area.

Illumina has invested in 74 genomics startups through the accelerator, the firm said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.